Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Medicover AB (publ)    MCOV B   SE0009778848

MEDICOVER AB (PUBL)

(MCOV B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 10/26 12:24:50 pm
134.8 SEK   -1.89%
10/13MEDICOVER : Trading update Q3 - Robust recovery
PU
10/13MEDICOVER : Uppdatering tredje kvartalet - robust återhämtning
PU
10/13MEDICOVER : Trading update Q3 - Robust recovery
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medicover publ : Genetics partners with Illumina and Healthmetrix for large scale screening of Coronavirus SARS-CoV-2

share with twitter share with LinkedIn share with facebook
07/13/2020 | 11:46am EDT

July 13, 2020 - Medicover Genetics, Illumina, a global leader in genomics, and Healthmetrix, a Berlin digital-health start-up initiated a partnership to develop an integrated, anonymous, large-scale Coronavirus SARS-CoV-2 screening solution using NGS technology.Ifsuccessful, it would complement PCR testing in building and scaling up the testing capacity for COVID-19 as continuous testing remains essential until a therapeutical solution for the virus is identified.

On July 4-5,MVZ Martinsried,Medicover Genetics' central laboratory site in Germany, carried out the pilot test of large-scale genome sequencing (NGS). As part of the pilot program, 1.560 volunteers were anonymously tested free of charge for COVID-19, in the area of Neuried and surrounding villages next to Munich. The initiative aims to compare the power of Next-Generation-Sequencing, which enables the analysis of thousands of DNA sequences in parallel in a single run, with conventional PCR-testing, the current gold standard for SARS-COV-2 diagnostics. This technology, if it can be successfully applied in routine workflows, could be used to drastically increase testing capacity in the future.

Stefan Mehrle, Head of Medicover Genetics, talks about the importance of the project: Medicover Genetics has been making considerable efforts to provide ample testing capacity to detect and contain COVID-19 outbreaks ever since the beginning of the pandemic. By using the expert knowledge in genetic testing combined with expertise in clinical virology and transfusion medicine at our central laboratory site in Martinsried, Medicover Genetics is aiming to expand its testing capacities even further. Using Next-Generation-Sequencing based SARS-CoV-2 diagnostics, we will be able to provide higher capacities at a more affordable price than it would be possible using conventional PCR. Combining this capacity with a streamlined digital workflow developed together with leading industry partners alongside of expanding the diagnostic testing solution, Medicover Genetics will be able to provide vastly increased testing capacities anywhere in Europe.

1.560 asymptomatic volunteers were enrolled in the pilot program and the samples were processed in the facilities of MVZ Martinsried, using NGS reagents and equipment provided free of charge by Illumina. Theresults were returned within 48 hours via LabRes®, a smartphone app created by Healthmetrix. The ambition is to establish a fully integrated workflow enabling anonymous testing from swab to result capable of processing large volumes simultaneously at affordable costs with an efficient reporting system.

Hanns-Georg Klein, Site-Head at MVZ Martinsriedreported: Not only were we able to successfully establish the technology in our laboratory and bring it to life in a matter of weeks, we also were able to report out all results in a smooth and timely manner to all volunteers within the expected timeframe. I am also proud to say that the team around Kaimo Hirv (Head of Lab Operations) and Oliver Wachter (Core Facility Lead) could clearly identify the four previously PCR-confirmed positive samples that were spiked into the sequencing run, proving that the technology is working under real-life conditions. The team on-site will now analyse the results of the experiment in more details and will improve the workflows and technology in order to make it fit for real world usage should the need arise.Hasso-Plattner-Institutein Potsdam near Berlin has also been involved and performed testing of students at their site to support the evaluation of the solution.

During the pilot study, antibody testing from blood samples was carried out to identify infections that occurred several weeks prior and further encourage the participation of citizens. MVZ Martinsried has performed these tests free of charge using reagents supplied my Mikrogen, another cooperation partner in the project. These results have also been successfully reported back to the participants through the LabRes® app by now.

Decentralizing laboratory testing and increasing the capacity to process million samples per week by using NGS technology, paired with a highly scalable citizen-centric approach based on smartphones, plays a critical role in finding a rapid solution to detect, manage and prevent COVID-19 transmission. Large scale screening is expected to support a safe return to work, school or the community, based on the early identification of outbreaks and containment.

About MVZ Martinsried

MVZ Martinsriedis a spin-off from the Institute of Clinical Chemistry at theLudwig Maximilian Universityof Munich, in 1998. The company sees its core competence as integrated in vitro diagnostics through the analysis of body fluids and tissues. The common denominators are the newest technology and latest findings from genome research. Initially, the focus was on building up a high-performance, innovative human genetic referral laboratory. The range of services was gradually expanded to include the fields of immunogenetics, clinical chemistry, molecular pathology, microbiology and virology; at the same time, genetic counseling centers were set up and a consultation service established. The unique characteristic of the company is the interdisciplinary, integrated diagnostic competence for physicians and patients (www.medizinische-genetik.de).

Since Jan 2019, MVZ Martinsried is part of Medicover - a leading international Healthcare and Diagnostic Services company founded in 1995 (www.medicover.com).

For further information, please contact:

Hanna Bjellquist, Head of IR

+46 703033272
hanna.bjellquist@medicover.com

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities,laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2019, Medicover had revenue around €844 million and 28,800 employees. For more information, go to www.medicover.com

Disclaimer

Medicover AB published this content on 13 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 July 2020 14:45:08 UTC


share with twitter share with LinkedIn share with facebook
All news about MEDICOVER AB (PUBL)
10/13MEDICOVER : Trading update Q3 - Robust recovery
PU
10/13MEDICOVER : Uppdatering tredje kvartalet - robust återhämtning
PU
10/13MEDICOVER : Trading update Q3 - Robust recovery
AQ
09/11MEDICOVER : nomination committee for the annual general meeting 2021
PU
09/11MEDICOVER : nomination committee for the annual general meeting 2021
AQ
09/01MEDICOVER : treats a growing number of Covid-19 patients in India
AQ
08/31MEDICOVER : Number of shares and votes in Medicover
AQ
07/24MEDICOVER PUBL : Interim report April-June 2020
AQ
07/16MEDICOVER PUBL : Invitation to media, investor and analyst call for Medicover Q2..
AQ
07/13MEDICOVER PUBL : Genetics partners with Illumina and Healthmetrix for large scal..
PU
More news
Financials
Sales 2020 944 M 1 115 M 1 115 M
Net income 2020 9,23 M 10,9 M 10,9 M
Net Debt 2020 265 M 313 M 313 M
P/E ratio 2020 206x
Yield 2020 0,09%
Capitalization 1 966 M 2 324 M 2 323 M
EV / Sales 2020 2,36x
EV / Sales 2021 2,02x
Nbr of Employees 28 800
Free-Float 41,9%
Chart MEDICOVER AB (PUBL)
Duration : Period :
Medicover AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDICOVER AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 11,98 €
Last Close Price 13,25 €
Spread / Highest target 16,1%
Spread / Average Target -9,60%
Spread / Lowest Target -29,3%
EPS Revisions
Managers
NameTitle
Fredrik Rågmark Chief Executive Officer & Director
Fredrik Stenmo Chairman
Benedikt von Braunmühl Chief Operating Officer-Diagnostic Services
John Paul Stubbington Chief Operating Officer-Healthcare Services
Joe Ryan Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
MEDICOVER AB (PUBL)26.52%2 324
CVS HEALTH CORPORATION-18.90%78 849
HCA HEALTHCARE, INC.-7.59%46 172
FRESENIUS MEDICAL CARE AG & CO. KGAA4.06%23 792
LABORATORY CORPORATION OF AMERICA HOLDINGS22.65%20 210
QUEST DIAGNOSTICS19.05%17 074